Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Amyotrophic lateral sclerosis type 21"
Page 1
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3.
Cochrane Database Syst Rev. 2022.
PMID: 35593746
Free PMC article.
Review.
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative condition that may cause dysphagia, as well as limb weakness, dysarthria, emotional lability, and respiratory failure. ...The trial p …
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegene …
The NGS technology for the identification of genes associated with the ALS. A systematic review.
Pecoraro V, Mandrioli J, Carone C, Chiò A, Traynor BJ, Trenti T.
Pecoraro V, et al.
Eur J Clin Invest. 2020 May;50(5):e13228. doi: 10.1111/eci.13228. Epub 2020 May 19.
Eur J Clin Invest. 2020.
PMID: 32293029
Free PMC article.
BACKGROUND: More than 30 causative genes have been identified in familial and sporadic amyotrophic lateral sclerosis (ALS). The next-generation sequencing (NGS) is a powerful and groundbreaking tool to identify disease-associated variants. ...The number of ge …
BACKGROUND: More than 30 causative genes have been identified in familial and sporadic amyotrophic lateral sclerosis (A …
Item in Clipboard
Drug treatment for spinal muscular atrophy type I.
Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF.
Wadman RI, et al.
Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD006281. doi: 10.1002/14651858.CD006281.pub5.
Cochrane Database Syst Rev. 2019.
PMID: 31825542
Free PMC article.
MAIN RESULTS: We identified two RCTs: one trial of intrathecal nusinersen in comparison to a sham (control) procedure in 121 randomised infants with SMA type I, which was newly included at this update, and one small trial comparing riluzole treatment to placebo in 10 child …
MAIN RESULTS: We identified two RCTs: one trial of intrathecal nusinersen in comparison to a sham (control) procedure in 121 randomised infa …
Item in Clipboard
Cite
Cite